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Abstract
Introduction: New therapeutic strategies to modulate the immune response of
human and equine allergic asthma are still under extensive investigation.
Immunomodulating agents stimulating T-regulatory cells offer new treatment
options beyond conventional symptomatic treatment or specific immunotherapy
for human and equine allergic airway diseases, with the goal of a homoeostatic
T-helper cell balance. The aim of this study was to evaluate the effects of a nebulized
gelatin nanoparticle-CpG formulation (CpG-GNP) with and without specific
allergens for the treatment of spontaneous allergic equine asthma as a model for
human asthma.
Methods: Twenty equine asthma-affected horses were treated either with CpG-
GNP alone or CpG-GNP with allergens. Two specific allergens were selected for
each horse based on history and an in-vitro test. Each horse received seven
administrations of the respective nebulized composition and was examined before
treatment, immediately after and 6 weeks after the treatment course.
Results: Clinical parameters such as breathing rate, indirect interpleural
measurement, arterial blood gases, amount of tracheal mucus and percentage of
neutrophils and cytokines in tracheal washes and serum samples were evaluated.
Treatment with CpG-GNP alone as well as in combinations with relevant allergens
resulted in clinical improvement of nasal discharge, breathing rate, amount of
secretion and viscosity, neutrophil percentage and partial oxygen pressure directly
after and 6 weeks after treatment. There were no significant differences between the
two treatments in clinical parameters or local cytokine profiles in the tracheal wash
fluid (IL-10, IFN-g, and IL-17). IL-4 concentrations decreased significantly in both
groups.
Conclusion: Nonspecific CpG-GNP-based immunotherapy shows potential as a
treatment for equine and possibly also human allergic asthma.
Introduction
Allergic airway diseases have increased over the last few
decades [1]. Equine asthma (Recurrent airway obstruction,
RAO, heaves) is among the most frequent equine allergic
airway diseases in the Northern Hemisphere [2, 3]. The
pathophysiology of equine asthma resembles that of human
allergic neutrophilic asthma and could serve as spontaneous
animal model [3, 4]. Pathophysiology includes cholinergic
bronchospasm, hypercrinia and dyscrinia, edema, airway
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neutrophilia, and airway remodeling, resulting in nasal
discharge, coughing, and poor performance [2–4]. Potential
allergic triggers are organic and inorganic substances from
hay dust and straw [2, 3]. The predominant stabling of
horses in box stalls in our latitudes increases the exposure to
these triggers. In addition, a genetic predisposition has been
reported [5]. The exact nature of those environmental
trigger factors for equine asthma, such as pollens, mold
spores or storage mites is still not known. The avoidance of
allergens (hay dust, mold spores from straw) currently
constitutes the most important therapeutic measure, besides
symptomatic therapy with glucocorticoids and bronchodi-
lators. As absolute avoidance of allergens is difficult to
impossible and treatment with long-term medications may
be associated with adverse effects, there is a great need for
new therapeutic concepts.
Immunotherapy provides a promising approach by stimu-
lating regulatory T cells (Treg), with the goal of reestablishing
the homeostasis of the disrupted T-helper cell balance.
Nanoparticle-bound CpG-ODNs (Cytosine-phosphate-gua-
nosine oligodeoxynucleotides, CpG-GNP) were reported as an
effective immunomodulatory treatment for human and equine
asthma [6–8]. CpG is recognized by a type of Toll-like receptor
(TLR9) within the endosomal compartments. This leads to a
stimulation of subclasses of T-lymphocytes (Th1, Treg) and
cytokine synthesis (IFN-g, IL-10).Macrophages, epithelial cells
and neutrophilic granulocytes expressing TLR9 have already
been detected in equine lungs [9]. The stimulation of the Th1
response in turn causes a downregulation of the allergen-
specific Th2-type response (Th2/Th1 shift). Furthermore,
regulatory cytokines such as the anti-inflammatory IL-10 are
upregulated [10].
Gelatin nanoparticles (GNP) are immunologically inert and
biodegradable [11]. They are inserted as carriers for the
oligodeoxynucleotides and prevent the premature degradation
of DNA through ubiquitous DNAses. Furthermore, the
absorption through endocytosis and thus the effect of the
CpG is increased in the target cells [11]. This delivery system is
efficacious in-vitro inBALcells and in-vivo in thehorse [7, 8, 12].
The goal of the present study was to determine whether
monotherapy with CpG-GNP alone is as efficacious for equine
asthma as CpG-GNP combined with specific allergens in a
protocol using inhalation therapy over a longer time period
compared to previous studies [7, 8]. For this purpose, clinical,
endoscopic, cytological, and immunological parameters were
determined both locally in the lungs and systemically.
Methods
Study design and patients
In this prospective randomized exploratory field study,
twenty horses (mean age 17 5 years; 15 geldings, 4 mares, 2
stallions; mean weight determined via weight tape 498 kg
 111 kg) with a chronic history (mean 7 5 years, range
1–19 years; mean disease onset 10 4 years) of equine
asthma were admitted to the study. The study was approved
by the regional legal agency for animal experiments of the
Government of Upper Bavaria, Germany (No. 55.2-1-54-
2531-31-10). All horse owners signed an informed consent
form. The study has been performed in compliance with the
guidelines for animal studies (ARRIVE) and clinical trials
(CONSORT). The subjects were randomly selected for one
of the two treatment groups via coin toss.
Inclusion criteria
The inclusion criteria were a raised breathing rate at rest
(>16/min), an increased abdominal breathing pattern,
pathological findings of pulmonary auscultation, increased
levels of neutrophilic granulocytes in the respiratory tract
(>25%), reduced arterial blood gas levels at rest (partial
oxygen pressure <90mmHg), increased interpleural pres-
sure (>15 cmH2O), inducible clinical signs upon contact
with dusty hay and straw, and resolution of clinical signs,
when the horse was kept outside [2]. All of the horses were
left in their customary stabling and feed conditions during
the entire study, and were examined in their home stables.
During the study (performed between June and November),
no changes occurred in the keeping or management of the
horses. In addition, none of the horses received any
additional medications for at least 8th weeks before the
start and throughout the duration of the study.
Allergy testing
A functional in-vitro test from whole blood (FIT) [13] was
carried out on all horses by the Institute for Immunology at
the University of Veterinary Medicine Hannover. The blood
was sent overnight by express delivery.
Intervention
One group (n¼ 11, allergen group) received CpG-GNP in
combination with two individually selected allergens
(Table 1). The second group (n¼ 9, CpG only group)
received only CpG-GNP1 [6]. The lower number of patients
in the pure CpG group was because of drop out for reasons
not correlated to the study (e.g., lameness with medical
treatment). Allergens were received from Artu Biologicals
Europe B.V. (Lelystad, the Netherlands) and diluted 1:1000
with phosphate buffered salt solution (PBS; Dulbeco,
Biochrom AG, Berlin, Germany) to avoid acute signs of
bronchospasm. The allergens for inhalation were selected
1Biomers GmbH, Ulm, Germany.
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based on history (local geographical distribution of the
allergens and seasonality of clinical signs) and allergy test
results. The amount of allergen extract was increased
gradually from 0.6ml (0.3ml per allergen) for two
inhalations, to 0.4ml per allergen for two inhalations,
followed by 0.5ml per allergen for two inhalations and
finally 0.6ml per allergen for the final seventh inhalation.
Nanoparticles were produced and loaded with CpG-ODN
2216 (Biomers GmbH, Ulm, Germany) as previously
described [7, 8]. Each inhalation utilized 187.5mg CpG-
ODN, bound to 3.75mg GNP and dispersed in 2.5ml highly
purified water (HPW), with a final concentration of 1.5mg/
ml GNP and 0.075mg/ml CpG-ODN.
The individual dosage of CpG-GNP remained the same in
both groups. The inhalation regimen was conducted with
Equine Haler1TM,2 and Aeroneb1 Go micropump neb-
ulizer3 as previously described [7, 8].
The seven inhalations in each horse were administered
every other day. The interventions were always carried out by
two individuals (SG, JS).
Clinical and laboratory evaluations
The first evaluation of the horses occurred before the
treatment (I) and included clinical evaluation, bronchos-
copy, and evaluation of pulmonary function parameters, as
well as cytological, immunological, and laboratory-chemical
parameters. The second evaluation (II) occurred after the
completion of the seventh inhalation 2 weeks later. The third
evaluation (III) occurred 6 weeks after the last treatment, in
order to determine any long-term effect.
The clinical examination was conducted as previously
reported [7, 8] and in accordance with established and
standardized scoring systems [2, 14, 15], where available.
The variables examined included the measurement of the
following: breathing rate at rest, breathing type (relative
units [RU] in the range of 0–4; where 0¼ no or little
movement in the ventral region of the flank, and 4¼ obvious
abdominal lift, heave line and nostril flaring) [14], nasal
discharge (RU in the range of 0–3; 0¼ none, 1¼mild,
2¼moderate, and 3¼ severe discharge), auscultation of
lungs and trachea (in the range of RU 0–4; 0¼ physiological,
1¼mild, 2¼moderate, 3¼ severe, 4¼wheezes/rhonchi) [2,
7, 8], and arterial blood gas parameters [15]. The partial
pressures of oxygen and carbon dioxide (PaO2, PaCO2) were
determined. The physiological values were set at 100mmHg
 5 mmHg for PaO2 and 40mmHg 5 mmHg for
PaCO2 [15]. The arterial blood gas values were measured
via the IRMA1 blood analysis system.4 The alveolar-arterial
oxygen gradient (AaDO2) was calculated according to the
current atmospheric pressure and the measured blood gas
values [AaDO2¼ (atmospheric pressure 47mmHg)
 0.2095- PaCO2 - PaO2] [15]. In addition, an endoscopic
examination and a quantification of secretion (grade 0–5,
0¼ none, clean, singular tracheobronchial secretion [TBS]
to 5¼ extreme, profuse amounts) [16] and viscosity (grade
1¼ fluid to 5¼ viscous) [16] of the TBS was performed.
Cytological examinations of the TBS samples were
performed to determine the percentage of neutrophils in
the total cell count after staining with Diff-Quick solution.5
Indirectmeasurement of themaximum interpleural pressure
differences (D Ppl max) was performed by a Venti-Graph via
esophageal probe [17].6
In order to monitor the tolerability of the treatment, the
patients were continuously observed throughout the dura-
tion of the experiment, with written record of any nasal
Table 1. List of individual chosen allergens for every horse in the allergen & CpG-GNP treatment group (n¼ 11 equine asthma-affected horses).
Allergen I Allergen II
Horse 1 Acarus siro (Flour mite) Alopecurus pratensis (Meadow foxtail)
Horse 2 Brassica napus (Rapeseed) Lepidoglyphus destructor (Storage mite)
Horse 3 Aspergillus fumigatus (Mold) Acarus siro (Flour mite)
Horse 4 Acarus siro (Flour mite) Dermatophagoides pteronyssinus (House dust mite)
Horse 5 Acarus siro (Flour mite) Dermatophagoides peronyssinus (House dust mite)
Horse 6 Aspergillus fumigatus (Mold) Acarus siro (Flour mite)
Horse 7 Lepidoglyphus destructor (Hay mite) Dermatophagoides pteronyssinus (House dust mite)
Horse 8 Aspergillus fumigatus (Mold) Dermatophagoides pteronyssinus (House dust mite)
Horse 9 Aspergillus fumigatus (Mold) Brassica napus (Rapeseed)
Horse 10 Brassica napus (Rapeseed) Non
Horse number 10 had only one positive allergen reaction in the allergy test.
2Equine HealthCare Aps, Hoersholm, Denmark.
3Aerogen, Galway, Ireland.
4Diametrics Medical incorporated, Keller Medical, Bad Soden,
Germany.
5Medion diagnostics, D€udingen, Switzerland.
6Boehringer Ingelheim, Germany.
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discharge (consistency and quantity), coughing (at rest and
during exercise), signs of bronchospasm (respiratory sounds
such as wheezing and whistling, flared nostrils, increased
abdominal breathing type), increased breathing rate at rest,
redness or swelling visible by endoscopy, follicular hyper-
plasia, or reduced arterial blood gas values. In addition, the
internal body temperature was measured regularly, and,
within the scope of the three examinations, a white blood cell
count, a differential blood count, and a fibrinogen test were
evaluated for signs of adverse systemic effects.
Tracheal wash was performed with 20ml of sterile saline.
Venous blood samples and tracheal wash fluid were
centrifuged and the supernatant was immediately frozen
with liquid nitrogen and stored at 808C until the samples
were evaluated. The concentration of the cytokines IL-4,
IL-10, and IFN-gamma were measured in both serum and
tracheal wash fluid, IL-17 was only evaluated in the tracheal
wash fluid. The equine sandwich ELISAs were carried out as
described before [18] in compliance with the manufacturer’s
protocol.7 Samples above the detection limit were diluted
with sterile sodium chloride solution and the ELISA was
repeated. The dilution factor was used to calculate the exact
concentration of the sample. Sodium chloride was also used
as negative control and results of photometric extinction
were subtracted from the detected values of the samples. In
some cases this led to values below the detection limit (after
subtraction of the negative control).
Statistical analysis
Sample size calculation was performed (one-tailed, Cohen‘s
d >1 for relevant clinical effect with a power of >0.8 and a
P¼ 0.05) with 12 subjects per group. For non-parametric
data, the Wilcoxon matched-pairs signed-rank test was used
for paired values (comparison within the groups) and the
Mann-Whitney test was used for unpaired data (comparison
between the groups). For multiple tests a Kruskal–Wallis test
with post hoc Dunn test was performed for clinical,
endoscopic, cytological, and biochemical parameters (ex-
cluding cytokine values). Only non-parametric tests were
used because of low numbers of individuals per group. All
statistical analyses were performed using the GraphPad
Prism 7 software.9 Results with a calculated value of P< 0.05
were considered as statistically significant (displayed as ;
P< 0.01 as ; P< 0.001 as ) and were reported as
mean SD for normally distributed data (clinical parame-
ter) or median with interquartile range (IQR) for not
normally distributed data (cytokine values) according to
Shapiro-Wilk test. The 95% confidence intervals (CI) were
calculated and presented in brackets. Effect size (Cohen’s d)
was assessed for each piece of data to quantify the effect
(mild, d¼ 0.2–0.3; moderate, d¼ 0.5; large, d> 0.8). The




The most frequently positive result (70%) was to rapeseed
(rs; Brassica napus) (Fig. 1a). Half of the equine asthma
horses reacted positively to mold mix (mm), tree early (te)
and mites such as Dermatophagoides pteronyssinus
(DermPt) and Acarus siro (AcS) (Fig. 1a). A sensitivity of
the equine asthma horses was also frequently observed to
herbage grain (hg; 45%), tree late (tl, 40%) and Lepidogly-
phus destructor (LepD; 35%). Birch (bi) and herbage (He)
were very infrequently positive (Fig. 1a). No horse reacted to
hazelnut (hz) (Fig. 1a). The most severe reaction (grade 4)
was observed with AcS (Fig. 1b), followed by other mites
such as DermPt, LepD, rs, mm, and hg (Fig. 1b).
Adverse effects
Throughout the entire study, no signs of local or systemic
adverse effects were observed as a result of the inhalation
treatment. No bronchospasm, endoscopically visible local
hyperemia, swelling, follicular hyperplasia, or reduced
arterial blood gas values were observed. Furthermore, no
increase in internal body temperature, number of leukocytes,
differential blood count, or fibrinogen was measured.
Comparison between the groups
Comparing the twogroups (CpGonly vs. allergengroup), there
was no significant difference at any time point of examination
concerning all measured parameters including breathing rate,
breathing type, lung auscultation, interpleural pressure,
alveolar-arterial gradient (AaDO2), oxygen partial pressure
(PaO2), percentage of neutrophils, nasal discharge, quantifica-
tion of secretion (mucus), and viscosity of secretion (Fig. 2).
Breathing rate
In the allergen group, the breathing rate showed no clinically
relevant decrease after seven inhalations (Fig. 2, Tables 2 and
3). In the subsequent 6-week interval without treatment, the
breathing rate markedly improved (Fig. 2, Tables 2 and 3)
and showed amean reduction of the breathing rate of 24% in
comparison to the initial value. In the CpG only group amild
to moderate clinical improvement (Fig. 2, Tables 2 and 3) of
7R&D systems, Minneapolis, USA.
9GraphPad software Inc., La Jolla. 8http://davidmlane.com/hyperstat/effect_size.htm, Robert Coe.
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the breathing rate of 15% was already observed upon
completion of the seven inhalations. This effect strongly
increased to mean reduction of 34% in the subsequent 6-
week period without treatment and was statistically
significant (Fig. 2, Tables 2 and 3) in comparison to the
initial value.
Breathing type
The breathing type in the allergen group was moderately
reduced by 39% after seven inhalations (Fig. 2, Tables 2 and
3). This effect increased in the subsequent six weeks to a 51%
improvement in comparison to the initial value (Fig. 2,
Tables 2 and 3). The effect was comparable in the CpG only
group, with an improvement of 32%, and corresponded to
the large clinical reduction of symptoms of 48% in
comparison to the initial value (Fig. 2, Tables 2 and 3).
Lung auscultation
In the allergen group, the pulmonary auscultation revealed a
mild improvement of 23% after seven inhalations (Fig. 2,
Tables 2 and 3). This effect doubled (Fig. 2, Tables 2 and 3) to
46% improvement over the subsequent 6 weeks in
comparison to the first examination. In the CpG only
group, a similar improvement (22%) in the clinical findings
occurred after the inhalation treatment (Fig. 2, Tables 2 and
3). The clinical effect doubled (46%) in the subsequent
interval without treatment (Table 2).
Interpleural pressure
n the allergen group, a very low (6%) improvement of the
interpleural pressures was observed (Fig. 2, Tables 2 and 3).
This value persisted over 6 weeks (Fig. 2, Tables 2 and 3). The
CpGonly group showed amild decrease of 8% in interpleural
pressure directly after the inhalation treatment, although a
high individual fluctuation was present. Six weeks after
treatment, therewasno further change (Fig. 2, Tables 2 and 3).
Oxygen partial pressure (PaO2)
In the allergen group, a mild increase (6%) in oxygen partial
pressure in arterial blood was determined after seven
inhalations (Fig. 2, Tables 2 and 3). This effect doubled
(12%) in the subsequent 6 weeks. The CpG only group
showed an initial low increase (4%), which tripled in the
subsequent 6 weeks to a value of 12% (Fig. 2, Tables 2 and 3).
Alveolar-arterial gradient (AaDO2)
The allergen group showed lowdecrease of theAaDO2 of 15%
after seven inhalations (Fig. 2, Tables 2 and 3). After 6 weeks a
large improvement (45%) from the initial examination was
detected (Fig. 2, Tables 2 and 3). In the CpG only group, no
improvement was observed directly after the inhalation
treatment (Fig. 2, Tables 2 and 3). A moderate improvement
(29%) was only observed after the subsequent 6 weeks
without further treatment (Fig. 2, Tables 2 and 3).
Nasal discharge
The nasal discharge decreased with a large clinical effect after
seven inhalations by 52% (Fig. 2, Tables 2 and 3) in the
allergen group, and almost persisted (45%) over the
subsequent 6 weeks. In the CpG only group, this decrease
was moderate with 38% (Fig. 2, Tables 2 and 3). This effect
also almost persisted (31%) over 6 weeks (Tables 2 and 3).
Quantification of secretion (Mucus)
In the allergen group, a large clinical decrease by 42% in the
quantity of secretion in the trachea was observed after seven
inhalations (Fig. 2, Tables 2 and 3). This effect persisted and
improved over 6 weeks with a 60% decrease in comparison to
the initial value. In the CpG only group, a moderate decrease
in quantity of secretion was also observed, with a decrease of
31% after seven inhalations with a persistent effect (35%)
demonstrable over 6 weeks (Fig. 2, Tables 2 and 3).
Figure 1. Proportionate results from allergen tests concerning individual
allergens (a, b). Numbers and colors illustrate individual reactivity of type I
immunoreaction and horses: 0¼ no reaction, 1¼ clearly positive to
4¼ high grade positive (He, herbage; pl, pollen late; mm, mold mix; hg,
herbage grain; te, tree early; tl, tree late; bi, birch; hn, hazelnut; rs, rape;
LepD, Lep. Destr.; DmPt, Derm. Pteron.; AcS, Acarus siro).
J. Klier et al. Nanoparticulate CpG immunotherapy
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Figure 2. Relative decrease or increase [%] of breathing rate and pattern (calculated value of P< 0.05 displayed as ; P< 0.01 as ; P< 0.001 as ),
lung auscultation, interpleural pressure measurement, oxygen partial pressure, AaDO2, percentage of neutrophils in TBS, nasal discharge, endoscopic
quantiﬁcation of secretion and viscosity depicted in percent between ﬁrst and second (I–II) and ﬁrst and third (I–III) examinations and in comparison
between combined allergen and CpG-GNP treatment group (n¼ 11 equine asthma-affected horses) and pure CpG-GNP (n¼ 9 equine asthma-affected
horses) group (mean SD).
Nanoparticulate CpG immunotherapy J. Klier et al.
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Viscosity of secretion
In the allergen group, a large clinical decrease of 41% in the
viscosity of secretion was observed after the seventh
inhalation treatment (Fig. 2, Tables 2 and 3). This continued
to improve in the subsequent six weeks without further
treatment to 60% in comparison to the initial value (Fig. 2,
Tables 2 and 3). A large clinical improvement was also
observed in the CpG only group (40%) after seven
inhalations with a persistent effect demonstrable over 6
weeks (Fig. 2, Tables 2 and 3).
Percentage of neutrophils
The allergen group showed a mild decrease in the percentage
of neutrophilic granulocytes in the respiratory tract after
seven inhalations by 10% (Fig. 2, Tables 2 and 3). This effect
improved slightly in the 6 weeks without treatment to 17%
reduction. The CpG only group showed no improvement of
neutrophils (Fig. 2, Tables 2 and 3) with high individual
scattering. After 6 weeks, a very mild increase of the
neutrophilic granulocytes in the respiratory tract was
determined in comparison to the initial value (Tables 2
and 3).
Horses summarized
If all CpG-GNP treated horses are summarized, independent
of additional allergen administration (because of no
statistical significant difference between the groups) high
significant improvements directly after inhalation treatment
and after 6 weeks without further treatment could be
detected concerning breathing rate, breathing type, partial
oxygen pressure, nasal discharge, auscultation, amount of
mucus, and viscosity within the trachea (Fig. 3, Table 4).
Cytokines
Interleukin-4
The concentration of the cytokine IL-4 varied greatly among the
horses from 7.8pg/ml to 900,000pg/ml, and thus was partially
below and above the limit of detection (15.6–2,000pg/ml).
Overall, IL-4 was downregulated (Fig. 4). The concentration of
IL-4 in the tracheal wash sample was reduced after the last
inhalation, independent of the group (P¼ 0.0217) and also
decreased after another 6 weeks (P¼ 0.0070), in comparison to
the initial value. In comparison to the initial value, the median
decrease was 14% directly after the inhalation treatment, and
64% 6weeks after the last inhalation. In the serum, a decrease in
Table 3. Cohen's d, conﬁdence interval (CI) and P-value calculated from breathing rate, breathing type, lung auscultation, interpleural pressure
measurement, oxygen partial pressure (PO2), AaDO2, neutrophil percentage ofTBS, nasal discharge, endoscopic quantiﬁcation of secretion (mucus) and
viscosity from proportional values [%] between ﬁrst and second (I–II) or ﬁrst and third (I–III) examination from allergenþCpGgroup (allergen) versus CpG
only group (CpG).
Breathing rate Breathing type Auscultation Interpleural pressure
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Figure 3. Absolut values of all CpG-GNP treated horses (n¼ 20) at ﬁrst (I) examination before inhalation treatment, after seven inhalations (II) and after
six weeks without any treatment for evaluation of ongoing effect (III) of breathing rate [1/min], breathing type [RU 0–4], lung auscultation [RU 0–4],
interpleural pressuremeasurement [cmH2O], oxygen partial pressure (PO2) [mmHg], AaDO2 [mmHg], neutrophil percentage of TBS [%], nasal discharge
[RU 0–3], endoscopic quantiﬁcation of secretion (mucus) [RU 0–5] and viscosity [RU 0–5] (calculated value of P< 0.05 displayed as ; P< 0.01 as ;
P< 0.001 as ; meanSD).
J. Klier et al. Nanoparticulate CpG immunotherapy
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the concentration of IL-4 could only be observed after 6weeks (a
median decrease of 45%, P¼ 0.0186). Therefore, a long-term
effect over 6weeks could beobserved both in the serumaswell as
in the tracheal wash sample, independent of the group (Fig. 4).
Interleukin-10
The concentrations of IL-10 greatly varied initially among the
horses from78pg/ml to>400,000pg/ml, andwere in part above
orbelowthe limitofdetection(156.2–20,000pg/ml).Therewasa
short upregulation of IL-10 in the tracheal sample directly after
treatment. In contrast, the IL-10 upregulation in the serum
samplewas delayed.Over the 6weekperiod the concentration of
IL-10 decreased in the tracheal wash sample comparable to the
decrease of IFN-g. In the local tracheal wash sample there was a
median increase of IL-10 of 21% after inhalation treatment in
comparison to the baseline. After 6 weeks a decrease of 37%
could be detected in comparison to the sample taken after
inhalation treatment.Altogether IL-10 showedadecreaseof 25%
from the first to the last examination. In the serum samples,
independent of the groups, amedian increase of 20% could only
be detected 6 weeks after inhalation treatment in comparison to
the baseline (Fig. 4). However, none of those changes were
statistical significant.
Interferon-g
A median increase of 16% in concentration of the Th1-type
cytokine IFN-g could be detected directly after the inhalation
therapy in the tracheal wash sample. In contrast, a decrease of
43% was observed after 6 weeks in comparison to the sample
taken directly after treatment (Fig. 4). The median of the
relative decrease was 33% in comparison to the baseline.
However, none of those changes were statistically significant.
In the serum sample, a nonsignificant median increase of
23% could be detected directly after the inhalation
treatment. After 6 weeks there was a median decrease of
43% in comparison to the sample taken directly after
inhalation treatment (P¼ 0.0057). Altogether, a demonstra-
ble decrease in IFN-g of 30% could be seen after 6 weeks in
comparison to the baseline (Fig. 4) (P¼ 0.0035).
Interleukin-17
The concentration of IL-17 was only measured in the local
tracheal wash samples. The values measured diverged greatly
within and between both groups, in the initial concen-
trations, as well as in the samples taken directly after the
inhalation treatment and 6 weeks later, with no significant
Table 4. Cohen‘s d, conﬁdence interval (CI) and P-value from all horses calculated from breathing rate, breathing type, lung auscultation, interpleural
pressure measurement, oxygen partial pressure (PO2), AaDO2, neutrophil percentage of TBS, nasal discharge, endoscopic quantiﬁcation of secretion
(mucus) and viscosity from absolute values between ﬁrst and second (I–II) or ﬁrst and third (I–III) examination from all CpG treated horses (allergen group
and CpG only group) summarized (calculated value of P< 0.05 displayed as ; P< 0.01 as ; P< 0.001 as ).
Breathing rate Breathing type Auscultation Interpleural pressure
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Figure 4. IL-4, IL-10, and IFN-g concentration [pg/ml] in tracheal wash samples and serum of equine asthma-affected horses at ﬁrst (I) examination
before inhalation treatment, after seven inhalations (II) and after 6 weeks without any treatment to evaluate ongoing effect (III). All horses (n¼ 20)
independent of the group are depicted. Serum IFN-g all horses: nine points are under detection limit. Tracheal wash IFN-g: ﬁve points are under detection
limit. Calculated value of P< 0.05 displayed as ; P< 0.01 as ; P< 0.001 as  (individual values as scattered dot plot and median with interquartile
range are depicted).
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changes between time points. In addition, there was no
significant change of the IL-17 concentrations and the
neutrophilic granulocytes in the tracheal wash samples.
Comparison between the groups
Comparing the twogroups, therewasno significant difference
in the concentrations of cytokines at any time point.
Discussion
Nanoparticle-bound CpG-ODN immunotherapy offers an
allergen-independent effective and innovative treatment
approach of equine asthma-affected horses with ongoing
clinical improvement.
According to the results of this study there seemed to be no
need for allergy testing and adding allergens to the CpG-GNP
immunotherapy. In this study it was possible to achieve the
same clinical and immunological effects with exclusive CpG-
GNP therapy. This is particularly relevant in light of the fact
that it is tremendously difficult to determine the clinical
relevance of the positive test reactions for individual allergens.
The combination of specific allergens and the immuno-
modulatory CpG-ODN is similar to what was reported by
Senti et al. [6] in human patients with allergic asthma and
rhinitis. In that study, CpG-ODN was packed in virus-like
particles as adjuvants, and administered subcutaneously
with house dust mite allergens, which led to a clinical
remission of at least 38 weeks [6].
The use of nanoparticle-bound CpG-ODN for immuno-
modulatory monotherapy of horses with equine asthma has
already been reported [6, 7]. The biodegradable gelatin
nanoparticles are well tolerated, immunologically inert, stable
for inhalation, and a successful drug delivery system [7, 8, 20].
In the present study, a functional in-vitro test (FIT) was
conducted to assist in the identification of offending allergens,
in addition to history andphysical examination. The results of
this test varied greatly which corresponds to the results of
other studies [21–28]. Numerous horses reacted to pollen
antigens, which should be associated with seasonal deteriora-
tion in the spring and summer months. However, the clinical
signs occurred predominantly year-round.
As determined by Bruennlein [26], the most frequent
positive reactions of the equine asthma horses examined
occur upon exposure to dust and storagemites. In particular,
mold spores were shown to play an important role in the
allergic reactions of equine asthma horses [22–25, 28–30].
Three horses showed no reactions in the FIT. Possibly, their
offending allergens were not represented in the limited
selection of tested allergens. Alternatively, there was no
allergic type I hypersensitivity component to their disease
which is the only type of hypersensitivity that commercially
available assays test for. Most likely types III and IV immune
reactions are also involved in the pathogenesis of equine
asthma [31] and those are missed with tests directly or
indirectly measuring IgE. IgE-mediated type I hypersensi-
tivity reactions are acute immune reactions with mast cell
degranulation due to cross-linking of cell-bound IgE
antibodies by antigens. This is in contrast to immune
complex (antibody-antigen complex) type III reactions with
an inflammatory response in blood vessels and tissue
characterized by complement fixation and ligation of Fc
receptors on leucocytes. Finally, type IV reactions are cell-
mediated, delayed reactions mediated by T cells. Further-
more, allergy tests prove only sensitization to an allergen, but
not its clinical relevance [26]. This can only be demonstrated
by a provocation test [32], which inmost cases is not possible
for practical and ethical reasons.
An excessive pro-allergic Th2 immune response cannot be
documented in all cases of equine asthma [33], probably due
to individual factors such as exacerbation phase, duration of
the disease, genetic, and exogenous trigger factors and
allergen load [34]. The initial concentration of IL-4 in the
horses varied greatly. This is in accordance with the results of
others studies [35–39] and shows the heterogeneous
immunological phenotypes of the disease.
A downregulation of the Th2 immune response and thus
the IL-4 secretion is expected by CpG-ODNs through the
activity of TLR9 [6, 7, 40–43]. Since IL-4 causes class
switching and IgE production in B cells [31, 44–46], its
downregulation is an important goal of the CpG-ODN
immunotherapy. However, the involvement of IgE in the
pathogenesis of equine asthma could not be shown in all
studies [31], it probably is only one aspect of this
multifactorial disease. Furthermore, type I, III, and IV
immune responses are probably involved in equine asthma,
depending on the phase of disease and individual varia-
tions [31, 47].
A recent pilot study showed clinical improvement of
horses with insect bite hypersensitivity after pure allergen
treatment [48]. Studies in which CpG-ODN was combined
with an allergen for immunotherapy showed that the IL-4
concentration decreased [44, 49], or interferon-gamma
increased [50]. This is in accordance with our study, where a
decrease of IL-4 in tracheal washes could be documented
directly and 6 weeks after the end of treatment. The IL-4
serum concentrations were markedly decreased only in the
final examination 6 weeks post treatment. Adding allergens
to the CpG-ODN inhalation showed no additional effect.
This corresponds to findings of other groups [52]. Higher
allergen concentrations or longer duration of the hyposen-
sitization may have led to different results [6, 53].
Overall, it may be concluded that a long-term decrease of
the pro-allergic Th2 cytokine IL-4 is a promising result of an
immunomodulatory inhalation treatment for equine
asthma.
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CpG-ODN is able to activate specific Treg cells and
increase the release of IL-10 [54], which can inhibit the Th2
as well as the Th1 immune response and thus the clinical
signs [10, 55]. Allergen immunotherapy has been shown to
increase IL-10 in cats with asthma [43] and dogs with atopic
dermatitis [56]. IL-10 only showed a short increase in the
tracheal wash sample, possibly due to an insufficient IL-10
response and a deficiency of Treg cells, similar to what is
reported for human asthma [57]. In contrast, IL-10
demonstrated a lasting increase in the serum sample. In a
previous in-vitro study, BAL cells of healthy horses formed
more IL-10 after CpG-ODN stimulation than those of
equine asthma horses [12]. In contrast, an in-vivo study
showed a significant increase of IL-10 in the BAL of equine
asthma horses after five inhalations of CpG-ODN [7].
Regardless of the IL-10 concentrations, inhalation of CpG-
ODN can achieve a persistent improvement of clinical signs
in horses with equine asthma as shown in this study and
former studies [7, 8].
In this study, IFN-g concentration in the tracheal wash or
in the serum showed a short increase directly after inhalation
treatment followed by a decrease in both groups after
6 weeks. This contrasts with a previous study [7] and the
expected Th2/Th1 shift [40], but indicates a reduction of the
inflammatory response with a long-term effect over 6
weeks [10, 18, 40, 58].
IL-17 is a chemotactic and activating molecule for
neutrophils, which are crucially involved in the pathogenesis
of equine asthma. It also stimulates the mucus secretion in
the bronchi [59–61]. In this study, it did not decrease in the
tracheal wash samples. There was also no direct correlation
to the percentage of neutrophils in the TBS. Furthermore,
the initial tracheal concentrations of IL-17 varied greatly
among horses. This fits to the reported local variations of
cytokines in asthma-afflicted horses probably due to genetic
factors, the disease stage, and varying environmental allergen
exposures [35–39, 62].
How much the immunological effects of the inhalation
with CpG-GNP in this study were achieved by the treatment
and how much seasonal weather changes such as colder
temperatures and damp weather with a decreased environ-
mental allergen load were contributing to the changes is
unclear [2, 51]. This could have been excluded by the
continuous stabling of the horses during the study, but
would not have corresponded with the practical objectives of
the study.
In this study protocol the number of inhalations was
increased from five to seven, compared to a previous
study [8], to examine the influence of more inhalations on
dyscrinia and hypercrinia, percentage of neutrophils in the
tracheal wash, arterial blood gas values and duration of the
clinical improvement. Similarly, the follow-up examinations
were extended from 4 [8] to 6 weeks post treatment, as
owners from the previous study had reported a longer
persistence of their horses’ clinical improvement than
4 weeks, which could be confirmed in this study. In
addition, the increase from five [8] to seven inhalations
demonstrated a further improvement in clinical parameters,
a decreased percentage of neutrophils in the trachea, amount
of secretion and viscosity, as well as an increased partial
oxygen pressure in arterial blood gas compared to the former
study [8].
The gradual increase in the allergen dose was conducted
similar to what is recommended for subcutaneous allergen
immunotherapy for atopic dermatitis [63] and was deter-
mined in another experiment (data not shown) with the aid
of a histamine inhalation provocation test to avoid any
bronchospasmor signs of dyspnea with the inhaled allergens.
The allergen dosage used was relatively low. In combination
with the low number of total applications this was very
different from a classical immunotherapy, which extends
over a period of months. The classical subcutaneous route of
administration would of course be an alternative and avoid
exposing the lungs directly to the allergen concentration.
Horses were left in their usual stabling environment
during this field study. A homogeneous group of patients
with identical duration of disease, individual triggers, and
sensitivities and environmental exposures is difficult to
obtain for this multifactorial disease. In addition, this field
study evaluated a clinical response of a treatment in practice
and thus should reflect the conditions seen in this
environment. As a consequence limitations of the study
are the heterogeneous horse population (age, breed,
duration of disease, different barns, and different bedding
materials), the relatively small number of horses and the
exploratory character of the field study. Overall, treatment of
equine asthma in horses offers many challenges such as
identifying the clinically relevant allergens from allergy tests
and addresses the multifactorial pathogenesis and the
manifold exogenous environmental factors influencing the
disease. However, CpG-GNP, with or without allergens,
provides an inhalation immunotherapy that seems effective
over at least six weeks for treatment-resistant horses with
chronic respiratory disease and may be of interest for the
therapy of human asthma.
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